Similarly, there was no difference in DFS or breast cancer-related OS between patients with IHC(3+) and IHC(2+)/FISH(+) tumors in patients who received a combination of chemotherapeutic and anti-HER2 drugs as standard adjuvant treatment, regardless of whether it was administered pre/post-operatively (n = 314; Fig. 1 C and D), or patients who did not receive any chemotherapy (n = 129; Fig. 1E F). The gene discussed is ERBB2; the disease is breast carcinoma.